Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
8.90 +0.09 (+1.02%) 03/14/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 8.90 unch (unch) 16:03 ET
Quote Overview for Fri, Mar 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.79
Day High
9.00
Open 8.87
Previous Close 8.81 8.81
Volume 1,804,000 1,804,000
Avg Vol 2,579,610 2,579,610
Stochastic %K 31.91% 31.91%
Weighted Alpha -23.91 -23.91
5-Day Change +0.04 (+0.45%) +0.04 (+0.45%)
52-Week Range 8.55 - 12.65 8.55 - 12.65
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,734,436
  • Shares Outstanding, K 307,240
  • Annual Sales, $ 528,300 K
  • Annual Income, $ -56,110 K
  • EBIT $ 33 M
  • EBITDA $ 44 M
  • 60-Month Beta 0.69
  • Price/Sales 5.12
  • Price/Cash Flow N/A
  • Price/Book 13.57

Options Overview Details

View History
  • Implied Volatility 48.36% ( -0.22%)
  • Historical Volatility 29.90%
  • IV Percentile 71%
  • IV Rank 38.57%
  • IV High 115.40% on 10/09/24
  • IV Low 6.26% on 10/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 205
  • Volume Avg (30-Day) 372
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 14,873
  • Open Int (30-Day) 15,128

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.00
  • Number of Estimates 5
  • High Estimate 0.04
  • Low Estimate -0.05
  • Prior Year -0.02
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.55 +4.15%
on 03/10/25
Period Open: 9.77
10.00 -11.00%
on 02/19/25
-0.87 (-8.90%)
since 02/14/25
3-Month
8.55 +4.15%
on 03/10/25
Period Open: 9.36
10.00 -11.00%
on 02/19/25
-0.46 (-4.91%)
since 12/13/24
52-Week
8.55 +4.15%
on 03/10/25
Period Open: 11.54
12.65 -29.64%
on 11/06/24
-2.64 (-22.88%)
since 03/14/24

Most Recent Stories

More News
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates

Puma Biotechnology PBYI reported fourth-quarter 2024 adjusted earnings of 43 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company reported adjusted...

FOLD : 8.90 (+1.02%)
IMCR : 28.80 (+1.87%)
PBYI : 3.32 (-0.60%)
PCRX : 22.87 (+0.79%)
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

FOLD : 8.90 (+1.02%)
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

FOLD : 8.90 (+1.02%)
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

FOLD : 8.90 (+1.02%)
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposiumâ„¢ 2025

FOLD : 8.90 (+1.02%)
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

FOLD : 8.90 (+1.02%)
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

FOLD : 8.90 (+1.02%)
Insider Sale: President and CEO of $FOLD (FOLD) Sells 7,500 Shares

Bradley L Campbell, the President and CEO of $FOLD ($FOLD), sold 7,500 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.8%...

FOLD : 8.90 (+1.02%)
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus

Rocket Pharmaceuticals, Inc. RCKT incurred a loss of 71 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 78 cents. In the year-ago quarter, the company...

FOLD : 8.90 (+1.02%)
IMCR : 28.80 (+1.87%)
CSTL : 19.29 (+2.83%)
RCKT : 8.76 (+3.06%)
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up

Puma Biotechnology, Inc. PBYI reported third-quarter 2024 adjusted earnings of 45 cents per share, which beat the Zacks Consensus Estimate of 35 cents. In the year-ago quarter, the company had reported...

FOLD : 8.90 (+1.02%)
IMCR : 28.80 (+1.87%)
PBYI : 3.32 (-0.60%)
CSTL : 19.29 (+2.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is...

See More

Key Turning Points

3rd Resistance Point 9.21
2nd Resistance Point 9.11
1st Resistance Point 9.00
Last Price 8.90
1st Support Level 8.79
2nd Support Level 8.69
3rd Support Level 8.58

See More

52-Week High 12.65
Fibonacci 61.8% 11.08
Fibonacci 50% 10.60
Fibonacci 38.2% 10.11
Last Price 8.90
52-Week Low 8.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals